AXONYX INC
10QSB, EX-27.1, 2000-08-14
PHARMACEUTICAL PREPARATIONS
Previous: AXONYX INC, 10QSB, EX-3, 2000-08-14
Next: UNIVERSAL ACCESS INC, 10-Q, 2000-08-14



<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-END>                               JUN-30-2000
<CASH>                                      11,264,000
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                            11,289,000
<PP&E>                                          31,000
<DEPRECIATION>                                   5,000
<TOTAL-ASSETS>                              11,366,000
<CURRENT-LIABILITIES>                          371,000
<BONDS>                                              0
                                0
                                          0
<COMMON>                                        15,000
<OTHER-SE>                                  10,980,000
<TOTAL-LIABILITY-AND-EQUITY>                10,995,000
<SALES>                                              0
<TOTAL-REVENUES>                               104,000
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                             1,307,000<F1>
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                            (2,910,000)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                        (2,910,000)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (2,910,000)
<EPS-BASIC>                                      (.20)
<EPS-DILUTED>                                    (.20)
<FN>
<F1>Research and Development
</FN>


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission